Jmol-3D images Image 1
Molecular formula C44H61N9O11
Molar mass 892.01 g mol−1
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)

Valorphin, also known as VV-hemorphin-5, is a naturally occurring, endogenous opioid heptapeptide of the hemorphin family with the amino acid sequence H-Val-Val-Tyr-Pro-Trp-Thr-Gln-OH.[1][2][3] It is produced in the body via proteolyic cleavage of residues 33-39 of the β-chain of hemoglobin.[2][4] Valorphin binds preferentially to the μ-opioid receptor and produces effects such as analgesia and self-administration in animals.[1][2] It also possesses cytotoxic and antiproliferative properties against tumor cells,[3][4][5][6] the mediation of which, on account of the fact that they are reversed by naloxone, appears to be dependent on the opioid receptors.[5]

See also


  1. ^ a b Maurer R, Römer D, Büscher HH, Gähwiler BH, Thies PW, David S (February 1985). "Valorphin: a novel chemical structure with opioid activity". Neuropeptides 5 (4-6): 387–90.  
  2. ^ a b c Erchegyi J, Kastin AJ, Zadina JE, Qiu XD (June 1992). "Isolation of a heptapeptide Val-Val-Tyr-Pro-Trp-Thr-Gln (valorphin) with some opiate activity". International Journal of Peptide and Protein Research 39 (6): 477–84.  
  3. ^ a b Blishchenko EY, Sazonova OV, Kalinina OA, et al. (May 2002). "Family of hemorphins: co-relations between amino acid sequences and effects in cell cultures". Peptides 23 (5): 903–10.  
  4. ^ a b Blishchenko E, Sazonova O, Surovoy A, et al. (August 2002). "Antiproliferative action of valorphin in cell cultures". Journal of Peptide Science : an Official Publication of the European Peptide Society 8 (8): 438–52.  
  5. ^ a b Blishchenko EYu, Mernenko OA, Mirkina II, et al. (1997). "Tumor cell cytolysis mediated by valorphin, an opioid-like fragment of hemoglobin beta-chain". Peptides 18 (1): 79–85.  
  6. ^ Blishchenko EY, Sazonova OV, Kalinina OA, et al. (January 2005). "Antitumor effect of valorphin in vitro and in vivo: combined action with cytostatic drugs". Cancer Biology & Therapy 4 (1): 118–24.